Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Piper methysticum (Kavain).
Piper methysticum exerts potent anxiolytic and sedative effects through the positive allosteric modulation of GABA-A receptors and the inhibition of voltage-gated sodium and calcium channels to modulate neurotransmitter release.
10635
290.4 g/mol
3.7
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Piper methysticum (Kavain) across standard consumer modalities.
The high hygroscopicity of concentrated kavalactone resins necessitates the use of moisture-resistant HPMC shells and specialized desiccants to prevent oil-out or shell brittleness.
High lipid loading of kavalactone extracts interferes with pectin gelation kinetics and produces a characteristic, often undesirable, numbing effect on the oral mucosa.
The substantial therapeutic dose required for kavalactones typically exceeds the 30mg payload capacity of standard thin-film polymer matrices, leading to structural failure.
Ready to launch a product featuring Piper methysticum (Kavain)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Piper methysticum (Kavain) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Piper methysticum (Kavain) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation